Eye Doctor and Fox News Regular Eyed as New Head of FDA Vaccine Division
FDA may pick Dr. Hemmati to lead CBER, which could speed up vaccine and biotech drug approvals, but decision is not final.
/ 4 items
#RNA↓
Wells Fargo gives Atrium Therapeutics a Strong Buy rating on its rare cardiomyopathy programs
Wells Fargo analyst initiates coverage on Atrium Therapeutics with Overweight rating and $25 price target, highlighting big potential in RNA therapies for rare genetic heart diseases with no current treatments.
Novartis Makes Bold $12 Billion Move with Avidity Biosciences Acquisition in Largest Deal Under CEO Narasimhan
Novartis acquires Avidity Biosciences for $12 billion, gaining access to breakthrough RNA therapeutics for neuromuscular diseases as the Swiss drugmaker prepares for upcoming patent expirations on key drugs.
Novartis Pursues Avidity: A Bid for Rare Disease Dominance
Novartis targets rare disease biotech Avidity Biosciences in a $4.3B takeover bid, aiming to boost its pipeline and offset major patent cliffs.